{{Link style|time=2015-12-11T07:39:18+00:00}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 437139289
| IUPAC_name = 1-(2-<nowiki/>{4-[3-(Trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-1,3-dihydro-2''H''-benzimidazol-2-one
| image = Flibanserin-structural.svg
| image2 = Flibanserin ball-and-stick model.png

<!--Clinical data-->
| tradename =  Addyi
| pregnancy_category =  
| legal_status = 研究性质
| routes_of_administration = [[口服|口服]]

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  ~11 小时[http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf]
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 8182
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 167933-07-5
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 6918248
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5293454
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 37JK4STR6Z
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02577
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 231068

<!--Chemical data-->
| C=20 | H=21 | F=3 | N=4 | O=1 
| molecular_weight = 390.40 g/mol
| smiles = FC(F)(F)c4cc(N3CCN(CCN2c1ccccc1NC2=O)CC3)ccc4
| InChI = 1/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)
| InChIKey = PPRRDFIXUUSXRA-UHFFFAOYAA
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PPRRDFIXUUSXRA-UHFFFAOYSA-N
}}
{{medical}}
'''氟班色林'''（{{lang-en|Flibanserin}}）（代号：'''BIMT-17'''），商品名为'''Addyi'''，研究发现是一种用来治疗绝经前妇女的[[性欲障碍|性欲障碍]]（HSDD）的药物。<ref>{{cite journal | doi = 10.1111/j.1527-3458.2002.tb00219.x | author = Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S|title = Pharmacology of flibanserin | journal = CNS Drug Rev.| volume = 8| issue = 2| pages = 117–142| date  = Summer 2002| pmid = 12177684}}</ref><ref>{{cite journal |author=Jolly E, Clayton A, Thorp J, Lewis-D’Agostino D, Wunderlich G, Lesko L |title=Design of Phase III pivotal trials of flibanserin in female Hypoactive Sexual Desire Disorder (HSDD) |journal=Sexologies |volume=17 |issue=Suppl 1 |pages=S133–4 |date=April 2008 |doi=10.1016/S1158-1360(08)72886-X }}</ref>氟班色林由[[勃林格殷格翰|勃林格殷格翰]]公司开发，但是在2010年10月得到了美国食品药品管理局（FDA）的负面评价。<ref name=spon>Spiegel online: [http://www.spiegel.de/wissenschaft/medizin/0,1518,722165,00.html Pharmakonzern stoppt Lustpille für die Frau], 8 October 2010 (in German)</ref>  随后制药权移交给了[[萌芽制药|萌芽制药]]（[[:en:Sprout_Pharmaceuticals|:en:Sprout Pharmaceuticals]]）继续研发，并于2015年8月取得了美国食品药品管理局的批准。

氟班色林可以在一个月有2-3次满意性行为的基础上比使用安慰剂多增加0.5-1次。<ref name=FDA2015>{{cite web|title=Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management (DSaRM) Advisory Committee|url=http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM449088.pdf|accessdate=5 June 2015|date=June 4, 2015}}</ref>

==参见==
* {{link-en|ABT-670|ABT-670}}
* {{link-en|ABT-724|ABT-724}}
* [[:en:Adatanserin|:en:Adatanserin]]
* [[布雷默浪丹|布雷默浪丹]]
* [[卡麦角林|卡麦角林]]
* [[:en:Intrinsa|:en:Intrinsa]]
* [[:en:Melanotan_II|:en:Melanotan II]]
* [[:en:PF-219061|:en:PF-219061]]
* [[普拉克索|普拉克索]]
* [[替勃龙|替勃龙]]
* [[UK-414495|UK-414495]]

== 参考文献 ==
{{reflist}}

[[Category:春药|Category:春药]]
[[Category:苯并咪唑|Category:苯并咪唑]]
[[Category:多巴胺激动剂|Category:多巴胺激动剂]]
[[Category:有机氟化合物|Category:有机氟化合物]]
[[Category:哌嗪|Category:哌嗪]]
[[Category:脲|Category:脲]]